1. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors
- Author
-
Alam N., Cortina-Borja M., Goetghebuer T., Marczynska M., Vigano A., Thorne C. European Paediatric HIV and Lipodystrophy Study Group in EuroCoord: T Goetghebuer, M Hainaut, A Vanderfaeillie, C Epalza, E Van der Kelen, J Levy, B Brichard, H Waterloos, V Schmitz, R Badolato, L Galli, R Rosso, G Secondo, C Viscoli, F Salvini, A Vigano, V Giacomet, V Fabiano, G V Zuccotti, Lo Vecchio A, E Nicastro, C Giaquinto, O Rampon, S Bernardi, G Pontrelli, H Tchidjou, C Gabiano, E Silvestro, F Mignone, A Maccabruni, M Marczynska, M Kaflik, S Dobosz, J Popielska, A Oldakowska, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, Alam, N., Cortina-Borja, M., Goetghebuer, T., Marczynska, M., Vigano, A., Thorne C., European Paediatric HIV and Lipodystrophy Study Group in EuroCoord: T Goetghebuer, M, Hainaut, A, Vanderfaeillie, C, Epalza, E Van der, Kelen, J, Levy, B, Brichard, H, Waterloo, V, Schmitz, R, Badolato, L, Galli, R, Rosso, G, Secondo, C, Viscoli, F, Salvini, A, Vigano, V, Giacomet, V, Fabiano, G, V Zuccotti, Lo Vecchio, A, E, Nicastro, C, Giaquinto, O, Rampon, S, Bernardi, G, Pontrelli, H, Tchidjou, C, Gabiano, E, Silvestro, F, Mignone, A, Maccabruni, M, Marczynska, M, Kaflik, S, Dobosz, J, Popielska, and A, Oldakowska
- Subjects
Pediatrics ,medicine.medical_specialty ,Lipodystrophy syndrome ,Adolescent ,Lipodystrophy ,Cross-sectional study ,Anti-HIV Agents ,HIV Infections ,Statistics, Nonparametric ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,Insulin resistance ,Risk Factors ,medicine ,Prevalence ,Humans ,Body Fat Distribution ,Pharmacology (medical) ,030212 general & internal medicine ,Child ,Children ,0303 health sciences ,030306 microbiology ,business.industry ,Stavudine ,HIV ,medicine.disease ,Antiretroviral therapy ,3. Good health ,Europe ,Infectious Diseases ,Cholesterol ,Cross-Sectional Studies ,Child, Preschool ,Immunology ,Body Composition ,Ritonavir ,Abnormality ,business ,Body mass index ,Fat abnormality ,medicine.drug - Abstract
Objectives: To estimate the prevalence of and identify risk factors for lipodystrophy syndrome (LS) and body fat abnormality in a population of HIV-infected children and adolescents. Design: Cross-sectional observational study. Methods: HIV-infected subjects aged 2-18 years were recruited from 15 HIV centers in Belgium Italy, and Poland between January 2007 and December 2008. Standardized assessments by the patient's long-term clinician were performed to establish the presence of abnormality. Risk factors were explored in logistic regression models for fat abnormality outcomes and LS (abnormality plus dyslipidemia). Results: Among 426 subjects (70% white), median age was 12.2 years (interquartile range: 9.0-15.0 years) and median duration of antiretroviral therapy was 5.2 years (interquartile range: 2.2-8.8 years). Prevalence was 57% (n = 235) for LS and 42% (n =176) for fat abnormality; 90 subjects with abnormality were affected in ≥3 locations. Lipoatrophy occurred in 28% (n =117) of subjects and lipohypertrophy in 27% (n = 115), most commonly in the face and trunk, respectively. In multivariable analysis, white ethnicity, body mass index, ritonavir/lopinavir, and nonnucleoside reverse transcriptase inhibitors were each associated with an increased risk of LS (P
- Published
- 2012